Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2003, 49, 147-159

https://doi.org/10.14712/fb2003049040147

Allogeneic Gene-Modified Tumour Cells in Metastatic Kidney Cancer. Preliminary Report

Giancarlo Pizza1, C. De Vinci1, G. Lo Conte1, A. Mazzuca1, G. Corrado1, D. Menniti1, A. Benati1, P. Romagnoli1, V. Fornarola1, L. Busutti2, A. Palareti3, R. Capanna4, V. Di Maio1, S. Ratini1, A. Gulino5, A. Vacca5, L. Melchiorri6, M. Ferrari7, S. Boriani8, R. O. Baricordi6

1Immunotherapy Module, Operative Unit of Urology, Department of Urology and Nephrology, S. Orsola-Malpighi Hospital, Bologna, Italy
2Operative Unit of Radiotherapy, Department of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
3Department of Computer Science, University of Bologna, Bologna, Italy
42nd Division of Orthopaedics and Reconstructive Surgery Centre, Florence, Italy
5Experimental Medicine, University "La Sapienza", Roma, Italy
6Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Ferrara, Italy
7Experimental Institute of Zoo-prophylaxis, Emilia-Romagna and Lombardia Regions, Brescia, Italy
8Operative Unit of Orthopaedics, Maggiore Hospital, Bologna, Italy

Received May 2003
Accepted May 2003

References

1. Antonia, S. J., Seigne, J. D. (2000) B7-1 gene-modified autologous tumour-cell vaccines for renal-cell carcinoma. World J. Urol. 18, 157-63. <https://doi.org/10.1007/s003450050190>
2. Arienti, F., Sulé-Suso, A., Melani, C., Maccalli, C., Belli, F., Illeni, M. T., Anichini, A., Cascinelli, N., Colombo, M. P., Parmiani, G. (1994) Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Human Gene Ther. 5, 139-1150. <https://doi.org/10.1089/hum.1994.5.9-1139>
3. ATCC Collection, CRL-1611.
4. Belldegrun, A., Tso, C. L., Sakata, T., Duckett, T., Brunda, M. J., Barsky, S. H., Chai, J., Kaboo, R., Lavey, R. S., McBride, W. H. (1993) Human renal carcinoma line transfected with interleukin-2 and/or interferon alfa gene(s): implications for live cancer vaccines. J. Natl. Cancer Inst. 85, 207-216. <https://doi.org/10.1093/jnci/85.3.207>
5. Brouwenstijn, N., Hoogstraten, C., Verdegaal, E. M., Van der Spek, C. W., Deckers, J. G., Mulder, A., Osanto, S., Schrier, P. I. (1998) Definition of unique and shared T-cell defined tumour antigens in human renal cell carcinoma. J. Immunother. 21, 427-34. <https://doi.org/10.1097/00002371-199811000-00004>
6. Bukowski, R. M. (1997) Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 80, 1198-1220. <https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H>
7. Bukowski, R. M. (2000) Role of immunotherapy in renal cell carcinoma. Medscape Oncology 3, (http://www.medscape.com/Medscape/oncology/journal/2000/v03.n01/mo5103.buko/mo5103.buko-01.html/)
8. Cavallo, F., Di Pierro, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Forni, M., Modesti, A., Forni, G. (1993) Protective and curative potential of vaccination with IL2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53, 5067-5070.
9. Chang, A. E., Li, Q., Jiang, G., Sayre, D. M., Btaun, T. M., Redman, B. G. (2003) Phase II trial autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884-890. <https://doi.org/10.1200/JCO.2003.08.023>
10. Corrado, F., Pizza, G., Martinelli, A., De Vinci, C., Menniti, D. (1984) Immunotherapeutic approach of kidney metastatic cancer using Immune-Rna (I-Rna) from guinea pigs immunized with formalin treated ATC. In: Advances in Urological Oncology and Endocrinology, eds. Bracci, U., Di Silverio, F., pp. 258-267, Acta Medica Publisher, Rome.
11. Coulie, P. G., Karanikas, V., Lurquin, C., Colau, D., Thierry Connerotte, T., Hanagiri, T., Van Pel, A., Lucas, S., Godelaine, D., Lonchay, C., Marchand, M., van Baren, N., Boon, T. (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 18, 33-42. <https://doi.org/10.1034/j.1600-065X.2002.18804.x>
12. Cullen, B. R. (1986) Trans-activation of human immunodeficiency virus occurs via a biomodal mechanism. Cell 46, 973-982. <https://doi.org/10.1016/0092-8674(86)90696-3>
13. De Vinci, C., Pizza, G., Severini, G., Cuzzocrea, D., Corrado, F. (1987) Immune-ribonucleic acid (I-RNA) in the treatment of metastatic renal cell carcinoma. J. Exp. Pathol. 3, 515-524.
14. Dillman, R. O., Barth, N. M., VanderMolen, L. A., Garfield, D. H., De Leon, C., O'Connor, A. A., Mahdavi, K., Nayak, S. K. (2001) Treatment of kidney cancer with autologous tumour cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother. Radiopharm. 16, 47-54.
15. Drake, W. P., Ungano, P. C., Mardiney, M. R. (1972) Preservation of cellular antigenicity of tumour cells by the use of formalin fixation. Cancer Res. 32, 1042-1046.
16. Elson, P. J., Witte, R., Trump, D. (1988) Prognostic factors in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313.
17. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., Klein, E. (1998) Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58, 2078-2080.
18. Gillis, S., Watson, J. (1981) Interleukin-2 dependent culture of cytolytic T-cell lines. Immunol. Rev. 54, 81-109. <https://doi.org/10.1111/j.1600-065X.1981.tb00435.x>
19. Graham, E. L., Vanderb, E. J. (1973) A new technique for the assay of infectivity of human adenovirus-5-DNA. Virology 52, 156-167. <https://doi.org/10.1016/0042-6822(73)90341-3>
20. Hersey, P., Bindon, C., Edwards, A., Murray, E. (1981) Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int. J. Cancer 28, 695-703. <https://doi.org/10.1002/ijc.2910280607>
21. Huland, E., Huland, H., Heinzer, H. (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol. 147, 344-8. <https://doi.org/10.1016/S0022-5347(17)37233-6>
22. Hrushsky, W. J., Murphy, G. P. (1977) Current status of therapy of advanced renal cell carcinoma. J. Surg. Oncol. 9, 277-281. <https://doi.org/10.1002/jso.2930090310>
23. Kalbfeisch, J. D., Prentice, R. L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, Inc., New York.
24. Kaplan, E. L., Meier, P. (1985) Non-parametric estimation from incomplete observations. J. Am. Stat. Ass. 457-481.
25. Koo, A. S., Tso, C. L., Shimabukuro, T., Peyret, C., deKernion, J. B., Belldegrun, A. (1991) Autologous tumour-specific cytotoxicity of tumour-infiltrating lymphocytes derived from human renal cell carcinoma. J. Immunother. 10, 347-354. <https://doi.org/10.1097/00002371-199110000-00006>
26. Lawrence, H. S. (1995) The transfer in humans of delayed hypersensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes. J. Clin. Invest. 34, 219-232. <https://doi.org/10.1172/JCI103075>
27. Levine, P. H., Pizza, G., Cannon, G., Ablashi, D. V., Armstrong, G., Viza, D. (1981) Cell-mediated immunity to Epstein-Barr virus-associated membrane antigens in patients with nasopharyngeal carcinoma. In: Nasopharyngeal Carcinoma, eds. Grundman, E., Krueger, G. R. F., Ablashi, D. V., pp. 137-144, Fisher-Verlag, Stuttgart.
28. Oosterwijk, E. E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494. <https://doi.org/10.1002/ijc.2910380406>
29. Pizza, G., Viza, D., Boucheix, C., Corrado, F. (1976) In vitro production of a transfer factor specific for transitional cell carcinoma of the bladder. Br. J. Cancer 33, 606-611. <https://doi.org/10.1038/bjc.1976.98>
30. Pizza, G., Viza, D., Boucheix, C., Corrado, F. (1977) Effect of in vitro produced transfer factor on the immune response of cancer patients. Eur. J. Cancer 13, 917-923. <https://doi.org/10.1016/0014-2964(77)90167-0>
31. Pizza, G., Viza, D., Fini, M., Cuzzocrea, D. E., Menniti, D., Corrado, F. (1980) Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses. Eur. Urol. 6, 45-47. <https://doi.org/10.1159/000473286>
32. Pizza, G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1984) Tumour regression after intralesional injection of interleukin-2 (IL2) in bladder cancer: preliminary report. Int. J. Cancer 34, 359-367. <https://doi.org/10.1002/ijc.2910340312>
33. Pizza, G., De Vinci, C. (1987) In vitro production of human antibodies against bladder cancer: characterization and diagnostic implications. J. Exp. Pathol. 3, 335-346.
34. Pizza, G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1987) Interleukin 2 in the treatment of infiltrating bladder cancer. J. Exp. Pathol. 3, 525-531.
35. Pizza, G., De Vinci, C., Aiello, A., Corrado, G., Lo Conte, G., Mazzuca, A., Baricordi, O. R., Vacca, A., Gulino, A., Fornarola, V., Capanna, R., Busutti, L. (1999) Gene immunotherapy in metastatic renal cell cancer (MRCC) using allogeneic tumour-cell line engineered with the human gene of interleukin-2 (IL2) and autologous formalin-fixed tumour cells: preliminary results in one patient. Urologia 66, 18-21. (supplement)
36. Pizza, G., De Vinci, C., Lo Conte, G., Maver, P., Dragoni, E., Aiello, E., Fornarola, V., Bergami, T., Busutti, L., Boriani, S., Palareti, A., Capanna, R. (2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120. <https://doi.org/10.1002/ijc.1426>
37. Pizza, G., De Vinci, C., Viza, D. (2002) Immunotherapeutic approaches for renal cancer. Folia Biol. (Praha) 48, 167-181.
38. Rabin, H., Hopkins, R. F. III., Ruscetti, F. W., Neubauer, R. H., Brown, R. L., Kawakami, T. G. (1981) Spontaneous release of a factor with properties of T-cell growth factor from a continuous line of primate tumour cells. J. Immunol. 127, 1852-1856. <https://doi.org/10.4049/jimmunol.127.5.1852>
39. Ross, C. E., Cochran, A. J., Hoyle, D. E., Grant, R. M., Mackie, R. M. (1975) Formalinized tumour cells in the leucocyte migration inhibition test. Clin. Exp. Immunol. 22, 126-132.
40. Ross, C. E., Cochrane, A. J., Hoyle, D. E., Grant, R. M., Mackie, R. M. (1973) Formalin-fixed tumour cells in the leukocyte migration test. Lancet 2, 1087-1088. <https://doi.org/10.1016/S0140-6736(73)92695-0>
41. Schwaab, T., Heaney, J. A., Schned, A. R., Harris, R. D., Cole, B. F., Noelle, R. J., Phillips, D. M., Stempkowski, L., Ernstoff, M. S. (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2b therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. 163, 1322-1327. <https://doi.org/10.1016/S0022-5347(05)67771-3>
42. Ueda, R., Ogata, S., Morrissey, D. M., Finstad, C. L., Szkudlarek, J., Whitmore, W. F., Oettgen, H. F., Lloyd, K. O., Old, L. J. (1981) Cell surface antigens: serological analysis of human renal cancer defined by mouse monoclonal antibodies: identification of tissue specific glycoproteins. Proc. Natl. Acad. Sci. USA 78, 5122-5126. <https://doi.org/10.1073/pnas.78.8.5122>
43. Vogelzang, N. J., Stadler, W. M. (1998) Kidney cancer. Lancet 352, 1691-1696. <https://doi.org/10.1016/S0140-6736(98)01041-1>
44. Yagoda, A., Abi-Rachmed, B., Petrylak, D. (1995) Chemotherapy for advanced renal cell carcinoma: 19831993. Semin. Oncol. 22, 42-60.
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive